Cellectis

cellectis.com

Cellectis is a clinical-stage biotechnology company leveraging its TALEN® gene-editing technology to develop allogeneic CAR T-cell therapies aimed at treating various cancers. Their innovative approach focuses on creating off-the-shelf immunotherapies that are broadly applicable, addressing significant challenges in the field such as Graft vs. Host Disease and treatment customization. With over 25 years of experience, Cellectis holds a strong intellectual property portfolio with more than 300 granted patents and has established global partnerships with leading companies like Allogene and AstraZeneca. Their pipeline includes promising product candidates like UCART22, targeting B-cell malignancies, showcasing their commitment to advancing cancer treatment.